Sign In
Buy TARS
$59.31
+1.17 (+2.01%)
At Close: Jul 13, 2026
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline
10:02am, Saturday, 11'th Jul 2026
Tarsus Pharmaceuticals NASDAQ: TARS said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company s
Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug
01:01pm, Thursday, 09'th Jul 2026
Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) on Wednesday acquired privately held iRenix Medical Inc., adding late-stage investigational ocular antiseptic IRX-101 to its ophthalmology pipeline.
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
02:12am, Thursday, 09'th Jul 2026
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
04:05pm, Wednesday, 08'th Jul 2026
IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care
All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy
01:01pm, Wednesday, 08'th Jul 2026
Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?
06:06am, Friday, 03'rd Jul 2026
Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Tarsus to Participate in Upcoming Investor Conferences
04:30pm, Thursday, 28'th May 2026
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise
10:43am, Friday, 15'th May 2026
Tarsus Pharmaceuticals (TARS) is reiterated as a Strong Buy, with a 12-month price target of $95 per share amid sector-wide healthcare weakness. Xdemvy's Q1 sales more than doubled YoY, but unchanged
IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but of
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
09:20pm, Tuesday, 12'th May 2026
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tarsus to Participate in Upcoming Investor Conferences
05:00pm, Thursday, 07'th May 2026
IRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript
09:41pm, Wednesday, 06'th May 2026
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates
07:31pm, Wednesday, 06'th May 2026
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.64 per share a year ago.
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
04:05pm, Wednesday, 06'th May 2026
Generated first quarter XDEMVY ® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
04:30pm, Wednesday, 29'th Apr 2026
IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m.
